J. Driscoll

发表

Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species

Y. Ran, B. Liederer, E. Choo, 2009, Xenobiotica; the fate of foreign compounds in biological systems.

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Adam R. Johnson, Jun Liang, J. DeVoss, 2013, Journal of medicinal chemistry.

Lead identification of novel and selective TYK2 inhibitors.

Adam R. Johnson, Jun Liang, M. Ultsch, 2013, European journal of medicinal chemistry.

Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase

J. Driscoll, J. Halladay, Donglu Zhang, 2016, Drug Metabolism and Disposition.

Novel mechanism for dehalogenation and glutathione conjugation of dihalogenated anilines in human liver microsomes: evidence for ipso glutathione addition.

Kevin A Ford, J. Driscoll, C. Hop, 2011, Chemical research in toxicology.

Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.

Christopher S. Poss, M. Hayward, J. Driscoll, 2007, Bioorganic & medicinal chemistry letters.

Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy

S. Markova, J. Driscoll, P. Vicat, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Biotransformation and bioactivation reactions – 2018 literature highlights

G. Miller, I. Rietjens, J. Driscoll, 2019, Drug metabolism reviews.

Novel advances in biotransformation and bioactivation research – 2020 year in review

G. Miller, A. Kalgutkar, I. Rietjens, 2021, Drug metabolism reviews.

Metabolism and Bioactivation: It's Time to Expect the Unexpected.

J. Driscoll, Corinne M Sadlowski, A. Feula, 2020, Journal of medicinal chemistry.

Bioactivation and reactivity research advances – 2021 year in review

G. Miller, J. Driscoll, Lloyd King, 2022, Drug metabolism reviews.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Adam R. Johnson, Jun Liang, J. DeVoss, 2017, Bioorganic & medicinal chemistry letters.

Metabolite Profiling and Reaction Phenotyping for the in vitro Assessment of the Bioactivation of Bromfenac.

J. Driscoll, N. Shah, T. Carlson, 2019, Chemical research in toxicology.

Biotransformation and bioactivation reactions of alicyclic amines in drug molecules

P. Worboys, J. Bolleddula, J. Driscoll, 2014, Drug metabolism reviews.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

M. Huband, A. Marfat, J. Driscoll, 2013, Bioorganic & medicinal chemistry letters.

A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.

G. S. Walker, A. Kalgutkar, A. Mutlib, 2007, Chemical research in toxicology.

Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.

M. Munchhof, T. Harris, J. Driscoll, 2010, Bioorganic & medicinal chemistry letters.

The identification of orally bioavailable thrombopoietin agonists.

A. Marfat, M. Munchhof, T. Harris, 2009, Bioorganic & medicinal chemistry letters.

Pyrimidine benzamide-based thrombopoietin receptor agonists.

M. Munchhof, J. Driscoll, Jonathan L. Doty, 2007, Bioorganic & medicinal chemistry letters.

Novel advances in biotransformation and bioactivation research—2019 year in review

G. Miller, I. Rietjens, J. Driscoll, 2020, Drug metabolism reviews.

Is There Enough Evidence to Classify Cycloalkyl Amine Substituents as Structural Alerts?

A. Kalgutkar, J. Driscoll, 2020, Biochemical pharmacology.

Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms

J. Driscoll, P. Dansette, J. Halladay, 2017, International journal of molecular sciences.

Role of Glucuronidation and P450 Oxidation in the Bioactivation of Bromfenac.

J. Driscoll, N. Shah, Aprajita Yadav, 2018, Chemical research in toxicology.

Elucidating the Mechanism of Tofacitinib Oxidative Decyanation.

J. Driscoll, C. Hop, Shuguang Ma, 2016, Drug metabolism letters.

Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.

A. Kalgutkar, J. Driscoll, J. O'Donnell, 2007, Chemical research in toxicology.

In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

S. Markova, J. Driscoll, R. Dick, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

Mark J. Mitton-Fry, M. Huband, A. Marfat, 2013, Bioorganic & medicinal chemistry letters.